
Please try another search
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, it is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein. The company has collaborations with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia.
Name | Age | Since | Title |
---|---|---|---|
Nicholas George Kirk | 60 | 2004 | Chief Executive Officer, Managing Director and Executive Director |
Jack Theseus Lowenstein | 66 | 2000 | Non-Executive Director |
Anthony Vincent Connon | 71 | 2007 | Non-Executive Director |
D. Williams | - | 2014 | Non-Executive Director |
Stephen B. Humphrys | - | 2014 | Non-Executive Director |
R. B. Kelly | - | 2014 | Chairman |
Martin S. Tallman | - | 2016 | Member of Scientific Advisory Board |
Roland Walter | - | - | Member of Scientific Advisory Board |
Borje S. Andersson | - | 2019 | Chairman of Clinical Advisory Board |
Douglas Smith | - | - | Member of Scientific Advisory Board |
Jaap-Jan Boelens | - | 2020 | Member of Clinical Advisory Board |
Jianjun Chen | - | 2021 | Member of Scientific Advisory Board |
Erin Howden | - | 2024 | Member of Scientific Advisory Board |
Serge Scrofani | - | 2024 | Independent Non-Executive Director |
James Breitenbucher | - | 2022 | Member of Scientific Advisory Board |
Daniel Tillett | - | 2019 | CEO, Managing Director & Director |
Peter M. Smith | 61 | 2023 | Executive Chairman |
Megan Baldwin | 50 | 2025 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review